The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers. Recent developments in genomic analysis and advances in bioinformatics have enabled the adoption of more personalized treatment approaches, such as neoantigen targeted therapies. Currently, several neoantigen-based therapies are being investigated in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab and nivolumab.
I have highlighted below some of the most interesting insights from our study. You can also access additional details here.
Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens that are generally overlooked during immune surveillance; these neoantigens have been shown to possess substantial therapeutic potential
Presently, over 130 neoantigen targeted therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration
Several molecules are in early stages of clinical development; based on delivery strategies, variety of vaccines and immunotherapies have been established for targeting personalized and shared antigens
Over the years, more than 6,000 patents related to neoantigens and affiliated therapies have been granted / filed; this is indicative of the heightened pace of research in this field
Both industry and academic players are contributing to the innovation, which is evident across published scientific literature focused on multiple targeted therapies for a myriad of cancer indications
Several investors, having realized the untapped opportunity within this emerging segment of cancer immunotherapy, have invested over USD 7 billion across 150 instances in the period between 2014 and 2019
The increasing traction in this field is also reflected in the partnership activity; deals inked in the recent past focused on a diverse range of therapies, involving both international and indigenous stakeholders
The market will receive the required impetus after approval of the first neoantigen targeted therapy; the future growth is likely to be driven by the successful clinical outcomes of the late-stage molecules
In fact, opinions from industry experts confirm the vast potential of this segment of cancer immunotherapy, capable of targeting personalized / off-the-shelf tumour antigens with multiple types of vaccines and therapies
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at firstname.lastname@example.org. Alternatively, you can place an Order by filling this Order Form.